UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28

Futu News19:34 · Ratings

Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?

Yahoo Finance03:50

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Benzinga03:29

Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says

MT Newswires01:27

U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood

Benzinga00:11

Teva Pharmaceutical Indus Analyst Ratings

BenzingaDec 18 23:03 · Ratings